You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)

    SBC: LUNG THERAPEUTICS INC            Topic: NHLBI

    Abstract Systemic sclerosissclerodermaSScis a chronic connective tissue disease in which lung fibrosis is the most frequent cause of deathSSc and idiopathic pulmonary fibrosis are the two most common disease that falls under the interstitial lung diseasesILDa grouping of devastating diseases in which lung fibrosis leads to progressive shortness of breatha very poor quality of lifeand death within ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)

    SBC: NANOHYBRIDS INC            Topic: N

    ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Enzymatic attachment of proteins to fluorescent nanodiamond surfaces.

    SBC: COLUMBUS NANOWORKS, INC.            Topic: 400

    Fluorescent nanodiamonds are biocompatibleinfinitely photostableand fluoresce in a variety of wavelengthsincluding the near infraredNIRregionThese characteristics suggest transformative applications in areas ranging from pure biological research to biomedical imagingwhere protein conjugated nanodiamonds could be targeted to specific tissues in living patients or even structures within individual c ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation of Airborne Particle Emissions from Commercial Products Containing Eng

    SBC: APPLIED NANOTECH, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): This multiphase STTR project will result in a standard method to evaluate the release of airborne particles from commercial products that contain engineered nanomaterials during their use or disposal. Carbon nanotubes (CNTs) are an important class of engineered nanomaterials that are incorporated into diverse products such as sporting goods, clothes, electronic ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Expansion of Immuno-CometChip Platform

    SBC: AMELIA TECHNOLOGIES LLC            Topic: NIEHS

    Project SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Farnesol as Novel Treatment in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)

    SBC: SPERAGEN, INC.            Topic: 102

    SUMMARY Succinic semialdehyde dehydrogenase deficiencySSADHDis a rare neurometabolic disease caused by mutations in the ALDH AgeneThe disorder is associated with significant developmental delay and extensive neurological morbidity including seizuresSeizures increase with agein patients as well as in experimental aldh adeficiencyaldh amicewhere seizures increase in frequency and severity starting a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Fluorescein for Sentinel Lymph Node Detection

    SBC: VESTAN INC            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II STTR project, Vestan Medical Imaging, Inc. will complete the development and clinical evaluation of its proprietary formulation of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer. Vestan will partner with the University of Utah Huntsman Cancer Institute (HC ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease

    SBC: Amprion, Inc.            Topic: NIA

    ABSTRACT This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluidswhich could be used for the biochemical diagnosis of Alzheimerandapos s diseaseADand related tauopathiesAD is the most common dementia in the elderly population and one of the leading causes of death in the develop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government